Pancreatic cancer or other disease that require pa ncreatoduodenectomy
Conditions
Interventions
Patients will receive a first-generation cephem antibiotic (CEZ) or a third-generation cephemantibiotic (CTRX) as a perioperative antimicrobial for pancreaticoduodenectomy.
Sponsors
Sugiura Teiichi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who planned to undergo pancreatoduodenectomy (2) Patients who performed endoscopic biliary stenting (EBS) for obstructive jaundice
Exclusion criteria
Exclusion criteria: (1) Patients without preoperative biliary drainage (2) Patients with bacteria detected in bile culturewithin 2 weeks prior to registration (3) Patients who planed to undergo total pancreatectomy (including residual total pancreatectomy) (4) Patients who received preoperativeradiotherapy (with or without chemotherapy) (5) Patients who planed to undergo combined major hepatectomy (two or more segments)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of surgical site infection (SSI) | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Incidence of Incisional SSI (2) Incidence of Organ/Space SSI (3) Results of postoperative drainage culture (4) Results of intraoperative bile culture (5) Incidence of other infectious complications (bacteremia, respiratory tract infection, urinary tract infection, infectious enteritis, etc.) (6) Incidence of pancreatic fistulas (ISGPF criteriagrade B and C) (7) Incidence of postoperative complications of Clavien-Dindo classification grade III or higher (8) Presence, type, and number of days oftherapeutic antimicrobials administered for postoperative infections (Total days from the second day after surgery to the day of discharge) (9) Postoperative hospital stays (10) Incidence of serious adverse events | — |
Contacts
Public ContactShinpei Otsuka
Shizuoka Cancer Center
Outcome results
None listed